Sarasota FL - (NewMediaWire) - March 08, 2019 - First National Energy Corp (OTC: FNEC) is pleased to announce that its wind turbine technology has entered the commercialization stage and is now prepared for full scale deployment throughout North America.The wind turbine technology has 23 years of proven reliability and performance, hundreds of installations that continue to perform efficiently, and has received several industry recognition awards. Customer trials have been successfully completed since the technology was installed in North America in 2016.After more than 2 years of North American customer trials, the Company has received interest from a number of large organizations looking to adopt First National’s wind turbine technology. Discussions continue with the companies that participated in the trials regarding the integration of the technology into existing business models.Further, the company is in the process of solidifying a partnership with an experienced Management & Technical Engineering Services firm to manage and execute the overall deployment of the technology throughout North America. This partnership is expected to be secured and announced within the coming days. Ongoing additional updates from the Company are available by following First National Energy on Twitter @FNECorpVideos from FNEC can be viewed on FNEC’s YouTube channel: https://www.youtube.com/channel/UCQS0HDos9FDsBIG2vkU2YZAFor further information about First National Energy Corp, please visit: www.firstnationalenergy.comAbout First National Energy CorpFirst National Energy is dedicated to international research and evaluation of various wind turbine designs and technologies. The Company has since found and successfully acquired the perfect autonomous renewable energy solution for multiple critical and non-critical power applications. The technology has more than 23 years of proven reliability and performance, industry recognition awards, and hundreds of installations that continue to perform efficiently to date. After many years, this technology has evolved to become a completely fine tuned and state of the art solution chosen exclusively by military, national telecom corporations, large scale mining operations, municipalities to augment public utilities in remote areas and private users. To date, this technology has successfully produced in excess of 12,000 Megawatts of electrical power. The Company has also forged strategic and commercial relationships with large scale leading power generation contractors, engineering firms, producers, and industry experts in order to support future commercialization and of this technology suite which is now positioned for major deployment in USA, Canada, Europe and India.Safe Harbor StatementThis news release contains statements that involve expectations, plans or intentions (such as those relating to future business or financial results, new features or services, or management strategies) and other factors discussed from time to time in the Company's OTC Market or Securities and Exchange Commission filings. These statements are forward-looking and are subject to risks and uncertainties, so actual results may vary materially. You can identify these forward-looking statements by words such as "may," "should,", "will", "expect," "anticipate," "believe," "estimate," "confident," "intend," "plan" and other similar expressions. Our actual results, such as the Company's ability to finance, complete and consolidate acquisition of IP, assets and operating companies, could differ materially from those anticipated in these forward-looking statements as a result of certain factors not within the control of the company such as a result of various factors, including future economic, competitive, regulatory, and market conditions. The company cautions readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The company disclaims any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such ...

Pulsed Shortwave Neuromodulation Therapy (ActiPatch®) Study in Chronic Lower Back PainFrederick, MD - (NewMediaWire) - March 8, 2019 - BioElectronics Corporation (OTC PINK: BIEL) http://www.bielcorp.com is pleased to announce the commencement of a clinical study investigating the efficacy of ActiPatch in treating chronic lower back pain. The objectives of this additional back pain study are to support Mundipharma’s Australia and New Zealand sales and marketing, provide local economic data for product reimbursement, and to document ActiPatch’s effectiveness on central sensitization pain.Chronic low back pain is very challenging to treat given its association with “central sensitization”, as sufferers experience exaggerated pain perception [2] and are often resistant to standard treatments. Sree Koneru, Ph.D., VP of Product Development at BioElectronics, said, “There is already real-world and clinical evidence that ActiPatch is effective in reducing back pain [3]. More than 30 million Americans are affected by chronic low back pain, collectively spending more than $90 billion annually in treatment costs [1]”.The study will involve 142 subjects who have been suffering with low back pain for more than 3 months at the time of enrollment into the study, which is scheduled to take place over a 30-day period and involve two visits. During the first visit, baseline data about the subject, including pain intensity, functionality and sleep quality will be collected. They will then receive, randomly, either an active or sham ActiPatch device along with instructions on how to use it for the next 30-days. During the final follow up visit, additional data will be collected to evaluate improvements in pain and other outcome measures. Full details about the study can be found at the NIH’s clinical trials listing page (https://clinicaltrials.gov/ct2/show/NCT03828864), as well as the Australian New Zealand Clinical Trials Registry (https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=12619000136101)The study is being conducted by the Pain Management Center of the prestigious Royal Prince Alfred Hospital in Sydney, Australia. The principal investigator (PI) leading the study is Graeme Campbell, a physiotherapist, supported by his team of physicians and clinical researchers.Dr. Sree Koneru, Ph.D. is presenting at the Australian Pharmacy Professional Conference RecoveryRx® Devices for chronic and post-operative wound care; Allay® Menstrual Pain Therapy. For more information, please visit www.bielcorp.com.Contact: Paul Knopick pknopick@eandecommunications.com 940.262.3584

Houston, TX - (NewMediaWire) - March 08, 2019 - D3esports, a division of StemGen, Inc. (OTC: SGNI), has launched its first Virtual to Real Motorsports Experience Center with the Visit Houston Marketplace in Houston, Texas. The custom-built SIMxlr8 game pod is a state-of-the-art three-screen simulator, complete with interactive steering wheel and pedals, as well as a real racing seat. It offers the user the opportunity to feel the rush of high-speed racing both in the virtual realm and on the race track. The D3esports experience on the VisitHouston.com website marketplace is currently in the Top 5 marketplace destination for visitors, rated higher than the NASA Space Center Experience. The D3esports Virtual to Real Racing Experience offers 45 minutes of virtual laps on a state-of-the-art simulator, followed by 15 minutes of real laps on the track in a professional race car. The location is at the MSR Houston circuit in the southern suburbs of Houston and offered to anyone 15 years or older for a fee of $575 USD. (See https://experience.visithouston.com/checkout/3/visit-houston/8/houston-marketplace/product/14908/virtual-to-real-racing-experience) The SIMxlr8 game pod is evolutionary, patent-pending and fully upgradeable for a true driving experience and built by actual racers who know how to win on the track and online. After the Virtual to Real experience there is an opportunity to rent and get behind the wheel of a prototype race car and learn about aerodynamic with more to come on this virtual to real education platform. “Our engineers and drivers believe we have the best simulator products on the market for personal, educational, and commercial use,” said Simon Dawson, CEO/President of StemGen and D3esports. “The launch of the VisitHouston.com Virtual to Real Motorsports Experience Center has been incredibly successful in a short amount of time. The SIMxlr8 products line has been used in successful commercial and hospitality applications. When you become a retail or distributor partner, you have an instant new profit center. We’re excited about the interest in these Experience Centers and have big plans to open many more in the coming months and have global plans with this program.” As D3esports grows the virtual to real gaming platform in the motorsports industry, additional D3esports Experience Centers are planned to be launched in the coming months, including internationally. For more information on either the Experience Center or purchase of the D3esports game pods, contact info@d3esports.com. D3esports was founded in May 2018 and launched in July 2018 at Dave and Buster’s Houston flagship location. Through their D3 division, the company has extensive experience in real motorsports for over 40 years.ABOUT STEMGEN, INC.StemGen, Inc. (https://stemgencorp.com/), a Delaware corporation based in Angleton, Texas, is a virtual to real gaming platform in the motorsports industry. NOTICE REGARDING FORWARD LOOKING STATEMENTSSafe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipate” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.CONTACT: Barbara J. Burns, BurnsGroup PR barbara@burnsgrouppr.com or +1 770-329-7134

Industry Veteran John P. Sentman to Lead Strategic Sales and PartneringMIRAMAR, FL - (NewMediaWire) - March 08, 2019 - Olaregen Therapeutix, a subsidiary of Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) is proud to announce the appointment of John P. Sentman as Vice President of Business Strategy. In his position, Mr. Sentman will lead and coordinate the activities and operations of the business strategy department responsible for executing all aspects of the organization’s overall business strategy, sales and market planning, and financial forecasts.Mr. Sentman has over 30 years of experience in commercial, marketing, and strategic planning roles within the medical device industry, primarily in the wound care field. He joins Olaregen from Integra Life Sciences where he was Senior Director of Global Marketing for Regenerative Technologies, overseeing brand marketing of the company’s soft tissue repair portfolio. Prior to Integra, Mr. Sentman held various sales, management, and marketing roles, both domestically and internationally over a 20-year career with ConvaTec, a leading manufacturer of wound care products. Mr. Sentman received his bachelor’s degree in finance from American University’s School of Business.“We are extremely pleased to have John leading business strategy, market development and the commercial launch of Excellagen,” said Anthony Dolisi, CEO of Olaregen and Chief Commercial Officer of Generex. “His extensive wound care experience and market knowledge will be instrumental to the company’s commercial success.”Mr. Sentman commented on his new position, “I welcome the opportunity to launch and build the Excellagen brand as the leading Cellular Tissue Product in treating hard-to-heal wounds, and I look forward to working closely with the Olaregen team.”About Generex Biotechnology Corp.Generex Biotechnology is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical laboratory, and medical device companies with new and approved products.Our newly formed, wholly-owned subsidiary, NuGenerex Distribution Solutions (NDS), integrates our MSO network with a pharmacy network, clinical diagnostic lab, durable medical equipment company (DME-IQ) and dedicated call center.About Olaregen TherapeuticsOlaregen Therapeutix, Inc. is a regenerative medicine company focused on the development, manufacturing and commercialization of products that fill unmet needs in the current wound care market. The company aims to provide advanced healing solutions that substantially improve medical outcomes while lowering the overall cost of care. Olaregen's first product introduction, Excellagen (flowable dermal matrix) is a topically applied product for dermal wounds and other indications. Excellagen is a FDA 510K cleared device for a broad array of dermal wounds, including partial and full thickness wounds, pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled/undermined wounds, surgical wounds (donor sites/ grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence), trauma wounds (abrasions, lacerations, second-degree burns and skin tears) and draining wounds, enabling Olaregen to market Excellagen in multiple vertical markets. Additionally, Excellagen can serve as an Enabling Delivery Platform for pluripotent stem cells, ...

NutraHempCBD celebrates St. Patrick’s Day with 40% off a 600mg Full Spectrum Tincture and a Pet Wellness Tincture combo!Coconut Creek, FL - (NewMediaWire) - March 8, 2019 - NutraHempCBD, a line of hemp-derived cannabidiol (CBD) products from the life sciences company, Nutralife Biosciences, Inc. (Nutralife or “the Company”) is celebrating St. Patrick’s Day by offering 40% off when you buy a 600mg Full Spectrum Tincture and a Pet Wellness Tincture! The promo price will be $80, that’s reduced from the original $135 sticker price.NutraHempCBD full spectrum cannabidiol formula has 600 mg of hemp-derived CBD in every bottle and has been hailed by consumers as a convenient way to reap the benefits of full-spectrum cannabidiol. This NutraHempCBD formula comes in an easy-to-dose spray instead of an oily dropper and customers can expect delivery of 14 mg of full-spectrum hemp-derived CBD per six-spray serving. The hemp utilized is grown on a USDA Certified Organic farm and the formula is flavored with stevia leaf extract for a superior taste.The NutraPet Drops are for your furry friends! Our pet CBD products are designed to provide anti-inflammatory and overall wellness factors. Our pet-friendly formula comes in convenient CBD drops that can be added directly to your pet’s favorite food or treat. The drops deliver 8.33 mg hemp-derived full spectrum CBD per serving and just like our human spray the CBD is from hemp grown on an organic farm.NutraLife Biosciences, Inc., formerly known as NutraFuels, Inc., (“NutraLife” or the “Company”) also recently announced a name change to NutraLife BioSciences, Inc. and new stock trading symbol, NLBS. The Company believes that the name, NutraLife BioSciences better reflects its current and planned future operations.The Company is a fully reporting company with a class of securities registered with the U.S. Securities and Exchange Commission (“SEC”). The Company recently announced its financial results for the three (3) and nine (9) month period ended September 30, 2018 with revenue of $1,062,146 and $2,870,462 respectively compared to $652,385 and $1,027,727 for the three (3) and nine (9) month period ended September 30, 2017. NTFU’s filings with the SEC can be viewed at www.sec.gov. NTFU’s CBD products and information about the company’s direct sales program can be found online atwww.nutrahempcbd.com and by following the company on Instagram.* These statements have not been evaluated by the Food and Drug Administration.* This product is not intended to diagnose, treat, cure or prevent any disease.Forward-Looking StatementsThis communication contains statements of a forward-looking nature. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. You can identify these forward-looking statements by words or phrases such as “may,” “will,” “except,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “future” or other similar expressions. The Company has based these forward-looking statements largely on the Company’s current expectations and projections about future events and financial trends that the Company believes may affect Company’s financial condition, results of operations, business strategy, and financial needs. There is no assurance that the Company’s current expectations and projections are accurate. All forward-looking statements in this press release are based on information available to the Company on the date hereof. These statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results to differ materially from those implied by the forward-looking statements. More detailed information about these risk factors are set forth in the Company’s filings with the Securities and Exchange Commission, including, but not limited to, those risks and uncertainties listed in the section entitled “Risk Factors,” in the Company’s Annual Report on Form 10-K with the Securities and Exchange Commission on April 17, 2018. The Company operates in a ...

New York, NY - (NewMediaWire) - March 8, 2019 - Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), engaged in building its business through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities and equity investments, today announced that it has placed an order with its manufacturer for the production of additional Tauri-Gum™ inventory at this time. The Company believes that this decision is prudent, due to stronger than expected initial indications of demand from a broad array of prospective distributors and customers. On March 7, 2019, the Company placed an order with its manufacturer for an additional 8,700 individual packs; delivery to the Company (for this 2ndinventory tranche) is expected during mid-April 2019. The Company continues to realize significant progress on a number of different initiatives and is excited for its upcoming commercial launch (later this month) of its CBD infused chewing gum product line, branded as Tauri-Gum™. In other news, the Company continues to be in productive discussions with Amazon and is hopeful that Tauri-Gum™ will be approved for listing, in the near term.ABOUT: TAURIGA SCIENCES, INC.Tauriga Sciences, Inc. (TAUG) is engaged in building business through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities. One such opportunity on which the Company has acted, involves the Company having entered into the cannabidiol (or “CBD”) infused chewing gum product business, as more fully described above and in prior press releases. This CBD infused chewing gum product has been branded under the following name: Tauri-GumTM. See also our periodic reports filed by us with the SEC for a more complete description of our business and material agreements that we have entered into. Further, the Company continues to identify and evaluate additional potential opportunities to generate revenue, as well as shareholder value, and leverage its resources and expertise to build a diversified and sustainable business model. Please visit our corporate website at www.tauriga.com. In addition, the Company is currently constructing an E-Commerce site for the sale of its CBD Infused Chewing Gum. This site is being constructed under the following URL address: www.taurigum.comForward-Looking StatementsThis press release contains certain “forward-looking statements” as defined by the Private Securities Litigation Reform Act of 1995 which represent management’s beliefs and assumptions concerning future events. These forward-looking statements are often indicated by using words such as “may,” “will,” “expects,” “anticipates,” believes, “hopes,” “believes,” or plans, and may include statements regarding corporate objectives as well as the attainment of certain corporate goals and milestones. Forward-looking statements are based on present circumstances and on management’s present beliefs with respect to events that have not occurred, that may not occur, or that may occur with different consequences or timing than those now assumed or anticipated. Actual results may differ materially from those expressed in forward looking statements due to known and unknown risks and uncertainties, such as are not guarantees of general economic and business conditions, the ability to successfully develop and market products, consumer and business consumption habits, the ability to consummate successful acquisition and licensing transactions, fluctuations in exchange rates, and other factors over which Tauriga has little or no control. Many of these risks and uncertainties are discussed in greater detail in the “Risk Factors” section of Tauriga’s Form 10-K and other filings made from time to time with the Securities and Exchange Commission. Such forward-looking statements are made only as of the date of this release, and Tauriga assumes no obligation to update forward-looking statements to reflect subsequent events or circumstances. You should not ...